The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $29.91

Today's change-0.44 -1.45%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $29.91

Today's change-0.44 -1.45%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Bio-Reference Laboratories Inc down (U.S.)$0.44

Bio-Reference Laboratories Inc closed lower Friday, dropping (U.S.)$0.44 or 1.45% to (U.S.)$29.91. Over the last five days, shares have gained 8.29% and 17.11% year to date. Shares have outperformed the S&P 500 by 4.41% during the last year.

Key company metrics

  • Open(U.S.) $30.27
  • Previous close(U.S.) $30.35
  • High(U.S.) $30.77
  • Low(U.S.) $29.72
  • Bid / Ask-- / --
  • YTD % change+17.11%
  • Volume743,527
  • Average volume (10-day)371,747
  • Average volume (1-month)252,912
  • Average volume (3-month)206,911
  • 52-week range(U.S.) $24.13 to (U.S.) $34.00
  • Beta0.85
  • Trailing P/E17.82×
  • P/E 1 year forward14.96×
  • Forward PEG1.45×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.68
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+5.62%

Based on its net profit margin of 5.62%, Bio-Reference Laboratories Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Healthcare Facilities
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedOct 31, 201410/31/2014Jul 31, 201407/31/2014Apr 30, 201404/30/2014Jan 31, 201401/31/2014
Revenue228222201181
Total other revenue--------
Total revenue228222201181
Gross profit1071028972
Total cost of revenue121120113109
Total operating expense197194182175
Selling / general / administrative76736865
Research & development--------
Depreciation / amortization--121
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income3128196
Interest income (expense), net non-operating---1-1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax3027185
Income after tax1815103
Income tax, total121282
Net income1815103
Total adjustments to net income--------
Net income before extra. items1815103
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1815103
Inc. avail. to common incl. extra. items1815103
Diluted net income1815103
Dilution adjustment--------
Diluted weighted average shares28282828
Diluted EPS excluding extraordinary itemsvalue per share0.660.550.370.11
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.660.550.370.11